International Journal of Cancer Management

Published by: Kowsar

Human Epidermal Growth Factor Receptor 2 Over-Expression in Patients with Esophageal Squamous Cell Carcinoma; Correlation with Response to Neo-Adjuvant Chemoradiation and Survival

Kazem Anvari 1 , Mehdi Seilanian Toussi 1 , Amir Aledavood 1 , Bahram Memar 2 , Mohammad Naser Forghani 1 and Mona Joudi 1 , *
Authors Information
1 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 Surgical Oncology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • International Journal of Cancer Management: March 2018, 11 (3); e8466
  • Published Online: March 27, 2018
  • Article Type: Research Article
  • Received: August 26, 2016
  • Revised: March 11, 2017
  • Accepted: February 25, 2018
  • DOI: 10.5812/ijcm.8466

To Cite: Anvari K, Seilanian Toussi M, Aledavood A, Memar B, Forghani M N, et al. Human Epidermal Growth Factor Receptor 2 Over-Expression in Patients with Esophageal Squamous Cell Carcinoma; Correlation with Response to Neo-Adjuvant Chemoradiation and Survival, Int J Cancer Manag. 2018 ; 11(3):e8466. doi: 10.5812/ijcm.8466.

Copyright © 2018, Cancer Research Center (CRC), Shahid Beheshti University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Di Pardo BJ, Bronson NW, Diggs BS, Thomas CJ, Hunter JG, Dolan JP. The Global Burden of Esophageal Cancer: A Disability-Adjusted Life-Year Approach. World J Surg. 2016;40(2):395-401. doi: 10.1007/s00268-015-3356-2. [PubMed: 26630937].
  • 2. Pourfarzi F, Barak M, Babaei M, Rahimi G, Malekzadeh R, Yazdanbod A. The features of esophageal cancer in ardabil province: Report of a population-based cancer registry in Northwest Iran. Govaresh. 2011;2011(16):1.
  • 3. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137-50. doi: 10.1200/JCO.2005.05.2308. [PubMed: 16682732].
  • 4. Sohda M, Kuwano H. Current Status and Future Prospects for Esophageal Cancer Treatment. Ann Thorac Cardiovasc Surg. 2017;23(1):1-11. doi: 10.5761/atcs.ra.16-00162. [PubMed: 28003586].
  • 5. Mimura K, Kono K, Hanawa M, Mitsui F, Sugai H, Miyagawa N, et al. Frequencies of HER-2/neu expression and gene amplification in patients with oesophageal squamous cell carcinoma. Br J Cancer. 2005;92(7):1253-60. doi: 10.1038/sj.bjc.6602499. [PubMed: 15785739].
  • 6. Berg D, Wolff C, Langer R, Schuster T, Feith M, Slotta-Huspenina J, et al. Discovery of new molecular subtypes in oesophageal adenocarcinoma. PLoS One. 2011;6(9). e23985. doi: 10.1371/journal.pone.0023985. [PubMed: 21966358].
  • 7. Pectasides E. Genomic Alterations and Targeted Therapy in Gastric and Esophageal Adenocarcinoma. Clin Ther. 2016;38(7):1589-99. doi: 10.1016/j.clinthera.2016.03.016. [PubMed: 27041412].
  • 8. Mandard AM, Dalibard F, Mandard JC, Marnay J, Henry-Amar M, Petiot JF, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 1994;73(11):2680-6. doi: 10.1002/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C. [PubMed: 8194005].
  • 9. Ishibashi H, Suzuki T, Suzuki S, Moriya T, Kaneko C, Takizawa T, et al. Sex steroid hormone receptors in human thymoma. J Clin Endocrinol Metab. 2003;88(5):2309-17. doi: 10.1210/jc.2002-021353. [PubMed: 12727990].
  • 10. Hardwick RH, Barham CP, Ozua P, Newcomb PV, Savage P, Powell R, et al. Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis. Eur J Surg Oncol. 1997;23(1):30-5. doi: 10.1016/S0748-7983(97)80139-4. [PubMed: 9066744].
  • 11. Lam KY, Tin L, Ma L. C-erbB-2 protein expression in oesophageal squamous epithelium from oesophageal squamous cell carcinomas, with special reference to histological grade of carcinoma and pre-invasive lesions. Eur J Surg Oncol. 1998;24(5):431-5. [PubMed: 9800975].
  • 12. Scheer M, Prange W, Petmecky K, Schirmacher P, Zoller JE, Kubler AC. [Evaluation of her-2/neu amplification/overexpression in OSCC with fluorescence in situ hybridization (FISH) and immunohistochemistry]. Mund Kiefer Gesichtschir. 2003;7(3):138-45. doi: 10.1007/s10006-003-0460-5. [PubMed: 12764679].
  • 13. Sato-Kuwabara Y, Neves JI, Fregnani JH, Sallum RA, Soares FA. Evaluation of gene amplification and protein expression of HER-2/neu in esophageal squamous cell carcinoma using Fluorescence in situ Hybridization (FISH) and immunohistochemistry. BMC Cancer. 2009;9:6. doi: 10.1186/1471-2407-9-6. [PubMed: 19128465].
  • 14. Friess H, Fukuda A, Tang WH, Eichenberger A, Furlan N, Zimmermann A, et al. Concomitant analysis of the epidermal growth factor receptor family in esophageal cancer: overexpression of epidermal growth factor receptor mRNA but not of c-erbB-2 and c-erbB-3. World J Surg. 1999;23(10):1010-8. doi: 10.1007/s002689900616. [PubMed: 10512940].
  • 15. Miyazono F, Metzger R, Warnecke-Eberz U, Baldus SE, Brabender J, Bollschweiler E, et al. Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer. 2004;91(4):666-72. doi: 10.1038/sj.bjc.6601976. [PubMed: 15213712].
  • 16. Akamatsu M, Matsumoto T, Oka K, Yamasaki S, Sonoue H, Kajiyama Y, et al. c-erbB-2 oncoprotein expression related to chemoradioresistance in esophageal squamous cell carcinoma. Int J Radiat Oncol Biol Phys. 2003;57(5):1323-7. doi: 10.1016/S0360-3016(03)00782-X. [PubMed: 14630269].
  • 17. Khan AJ, King BL, Smith BD, Smith GL, DiGiovanna MP, Carter D, et al. Characterization of the HER-2/neu oncogene by immunohistochemical and fluorescence in situ hybridization analysis in oral and oropharyngeal squamous cell carcinoma. Clin Cancer Res. 2002;8(2):540-8. [PubMed: 11839675].
  • 18. Zhan N, Dong WG, Tang YF, Wang ZS, Xiong CL. Analysis of HER2 gene amplification and protein expression in esophageal squamous cell carcinoma. Med Oncol. 2012;29(2):933-40. doi: 10.1007/s12032-011-9850-y. [PubMed: 21318736].
  • 19. Schoppmann SF, Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, et al. Expression of Her-2 in carcinomas of the esophagus. Am J Surg Pathol. 2010;34(12):1868-73. doi: 10.1097/PAS.0b013e3181f8be17. [PubMed: 21107094].
  • 20. Dreilich M, Wanders A, Brattstrom D, Bergstrom S, Hesselius P, Wagenius G, et al. HER-2 overexpression (3+) in patients with squamous cell esophageal carcinoma correlates with poorer survival. Dis Esophagus. 2006;19(4):224-31. doi: 10.1111/j.1442-2050.2006.00570.x. [PubMed: 16866851].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments